In vivo and in vitro study of co-expression of LMP1 and Cripto-1 in nasopharyngeal carcinoma

Ye, Qing; Li, Jing; Wang, Xiaoyan; Zhang, Xianzeng; Lin, Jun; Huo, Yuting; Sun, Zhengzhen; Xie, Shusen; Huang, Zheng

doi:10.1016/j.bjorl.2019.04.002

Cited by 4 publications

(3 citation statements)

References 39 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LMP-1 can therefore be used as biomarker in tumor progression and metastasis. 36 There is also promising use of immunotherapy in NPC with LMP-1–specific autologous cytotoxic lymphocytes–targeted therapy for recurrent disease. A vaccine based on LMP-1 has also shown tumor growth and metastasis suppression in mouse models; however, human trials are yet to be done.…”

Section: Discussionmentioning

confidence: 99%

Epstein-Barr Virus Latent Membrane Protein-1 Expression in Nasopharyngeal Carcinoma

Salano

Mwakigonja

Abdulshakoor

et al. 2021

JCO Global Oncology

View full text Add to dashboard Cite

PURPOSE Nasopharyngeal carcinoma (NPC), a malignant neoplasm of the epithelium covering the nasopharynx, is a rare disease in most parts of the world. Epstein-Barr virus (EBV), the most potent oncogenic virus, coupled with environmental and genetic factors has been identified to play a role in the development of NPC. An array of methods for detecting the virus do exist, from serologic detection of antibodies to DNA amplification. There is paucity of local data on the status of EBV infection in relation to NPC within the region, and this study attempts to shed more light on the subject. METHODS This was a retrospective cross-sectional laboratory-based study on histologically confirmed, archived tissues from July 2015 to June 2019. Immunohistochemistry expression of latent membrane protein-1 (LMP-1) was used to detect EBV infection in the tissues. RESULTS A total of 71 cases were enrolled in this study. The mean age was 47.87 years ± 16.84 years with a male-to-female ratio of 1.5:1. There was a unimodal distribution of EBV detection, with the peak (26.8%) at 36-45 years. About 45.1% of the 71 samples tested positive for LMP-1, all of which were nonkeratinizing carcinoma. Nonkeratinizing carcinoma was the most common histopathologic subtype (n = 67; 94.4%), with the majority (38 of 67; 56.7%) being undifferentiated and 29 of 67 (43.3%) differentiated. Keratinizing and basaloid subtypes had two cases each, representing 2.8%. CONCLUSION A significant proportion of NPC, particularly nonkeratinizing histologic subtype, seems to show LMP-1 positivity by immunohistochemistry, which may be adopted in resource-constrained settings to detect EBV infection in these tissue biopsies.

show abstract

Section: Discussionmentioning

confidence: 99%

Epstein-Barr Virus Latent Membrane Protein-1 Expression in Nasopharyngeal Carcinoma

Salano

Mwakigonja

Abdulshakoor

et al. 2021

JCO Global Oncology

View full text Add to dashboard Cite

show abstract

“…Whether CRIPTO regulates metastasis through its role as an autocrine or juxtacrine/paracrine factor is not fully understood. As a potential example of paracrine function, CRIPTO was shown to be elevated in nasopharyngeal carcinoma with metastasis and its expression was positively correlated with latent membrane protein 1 (LMP1), which acts as a CD40 functional homolog to prevent apoptosis of infected B-lymphocytes, potentially indicating a role of CRIPTO in the modulation of immune response [ 185 ]. This hypothesis is supported by independent findings that CRIPTO modulates macrophage cytokine secretion and phagocytic activity via NFκB signaling [ 86 ].…”

Section: Cripto’s Role In Cancermentioning

confidence: 99%

Whence CRIPTO: The Reemergence of an Oncofetal Factor in ‘Wounds’ That Fail to Heal

Freeman

Sousa

Karkampouna

et al. 2021

IJMS

View full text Add to dashboard Cite

There exists a set of factors termed oncofetal proteins that play key roles in ontogeny before they decline or disappear as the organism’s tissues achieve homeostasis, only to then re-emerge in cancer. Although the unique therapeutic potential presented by such factors has been recognized for more than a century, their clinical utility has yet to be fully realized1. This review highlights the small signaling protein CRIPTO encoded by the tumor derived growth factor 1 (TDGF1/Tdgf1) gene, an oft cited oncofetal protein whose presence in the cancer literature as a tumor promoter, diagnostic marker and viable therapeutic target continues to grow. We touch lightly on features well established and well-reviewed since its discovery more than 30 years ago, including CRIPTO’s early developmental roles and modulation of SMAD2/3 activation by a selected set of transforming growth factor β (TGF-β) family ligands. We predominantly focus instead on more recent and less well understood additions to the CRIPTO signaling repertoire, on its potential upstream regulators and on new conceptual ground for understanding its mode of action in the multicellular and often stressful contexts of neoplastic transformation and progression. We ask whence it re-emerges in cancer and where it ‘hides’ between the time of its fetal activity and its oncogenic reemergence. In this regard, we examine CRIPTO’s restriction to rare cells in the adult, its potential for paracrine crosstalk, and its emerging role in inflammation and tissue regeneration—roles it may reprise in tumorigenesis, acting on subsets of tumor cells to foster cancer initiation and progression. We also consider critical gaps in knowledge and resources that stand between the recent, exciting momentum in the CRIPTO field and highly actionable CRIPTO manipulation for cancer therapy and beyond.

show abstract

“…8 The most common causative agent for NPC other than genetics is Epstein-Barr Virus (EBV) which contributes to the malignant phenotype and plays a significant role in the development, metastasis, and invasion of NPC. 9 Viral infection causes carcinogenesis to occur faster with the proliferation of cancer cells and reduces apoptosis, while food and environment contribute to the neoplastic process and cancer development. 10 EBV infection is reflected by the Expression of Several EBV latent genes, including Latent Membrane Protein 1 (LMP-1) 11.…”

Section: Introductionmentioning

confidence: 99%

Association Between LMP-1 and p16 Expression with Prognostic Factor of Nasopharyngeal Carcinoma

Nur,

Karlowee,

Prasetyo

2023

magnamed

View full text Add to dashboard Cite

Background: LMP-1 and p16 expression are potential biomarkers for nasopharyngeal prognostic factors. EBV interferes with intracellular signaling processes related to cell cycle regulation and LMP-1, inactivating p16 expression and increasing cell proliferation. LMP-1 has been also reported to remove the promoter of p16 via methylation and inactivation of the p16 gene leads to uncontrolled proliferation of cell tumors.Objective: To analyze the association between LMP-1 and p16 expression with prognostic factors of nasopharyngeal carcinoma.Methods: This is a cross-sectional design analyzed that LMP-1 and p16 expression based on immunostaining of nasopharyngeal carcinoma. The patient clinical data used as prognostic factors are histopathological type, quality of life, TNM, and tumor stage. Statistical analysis used chi-square and spearman correlation.Results: Of the 61 patients, 49 were non-keratinizing carcinoma, undifferentiated type (80,3%). About 54 (88.5%) of the 61 samples are LMP-1 positive, 47 of which were non-keratinizing carcinoma. We figured out the significant association between the p16 expression with lymph node involvement (p=0.026) and staging (p = 0.196) in nasopharyngeal carcinoma. No correlation between LMP and p16 expression (p=0,134) (r=-0,194).Conclusion: p16 overexpression is associated with lymph node involvement and advanced stage in nasopharyngeal carcinoma

show abstract

In vivo and in vitro study of co-expression of LMP1 and Cripto-1 in nasopharyngeal carcinoma

Cited by 4 publications

References 39 publications

Epstein-Barr Virus Latent Membrane Protein-1 Expression in Nasopharyngeal Carcinoma

Epstein-Barr Virus Latent Membrane Protein-1 Expression in Nasopharyngeal Carcinoma

Whence CRIPTO: The Reemergence of an Oncofetal Factor in ‘Wounds’ That Fail to Heal

Association Between LMP-1 and p16 Expression with Prognostic Factor of Nasopharyngeal Carcinoma

Contact Info

Product

Resources

About